Faron Pharma chief "thrilled" at early cancer trial progress
Nine patients have been dosed so far with Clevegen, a new type of immune-oncology drug
Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 12 of 21
Investments and investor services
FTSE 100 closes lower Friday after lacklustre week
The FTSE 250 went the other way and gained over 87 points on Friday
Archive
Proactive news snapshot: 88 Energy, Tekcapital, AFC Energy, SDX Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Kibo Energy the day's top riser as its moves to secure total ownership of the Bordersley project
A look at the day's major movers, including 88 Energy, Two Shields, Inland Homes, Avingtrans, Creightons, RM2 and RPS Group
Faron says interim analysis supports continuation of INFORAAA trial
The ratio of the treatment arm versus placebo was two to one and mortality was assessed for a period of 30 days after surgery.
Archive
FTSE 100 still stuck in neutral; G20 meeting can't come soon enough
Bitcoin is up more than 10% but the shine has come off gold a bit
Investments and investor services
FireAngel Safety feeling the heat
A look at the day's major movers, starting with Shearwater, BlueRock, Frontier Smart Technologies, Science Group, MyCelx, Immotion, Biome and Cerillion
Archive
Proactive news snapshot: Faron Pharmaceuticals, Highlands Natural Resources, Immotion Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Faron getting to the bottom of the Traumakine conundrum
Faron expects to receive the interim results from the INFORAAA study of Traumakine in the near future, allowing a full review of all the Traumakine data with key opinion leaders, after which Faron will make the final decisions on Traumakine
Investments and investor services
FTSE 100 closes lower on day but up slightly on week as trade tensions still weigh
The UK's index of leading company shares closed Friday down nearly 23 points at 7,345
Archive
Wizz Air hopes to dodge problems facing budget airline sector
The day ahead includes full-year results from Wizz Air and Charles Stanley
Archive
Enjoy the UK bank holiday, because there will be little else to get excited about in the coming week
The shortened trading Week Ahead will only bring updates from the likes of second-liners FirstGroup, Pennon, Wizz Air, and Daily Mail & General Trust
Faron Pharma finance boss to transition into new role next month
Yrjö Wichmann is stepping down as CFO to become Faron’s new Vice President, Financing and Investor Relations, and he will be replaced by Toni Hänninen
Archive
Proactive news snapshot: Strategic Minerals, Westminster Group, Victoria Oil & Gas, ImmuPharma …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Sunrise Resources, Location Sciences, Eckoh ...
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Malvern surges after confirming attendance at investor conference
A look at the day's major movers, including Tricorn, Eagle Eye, Microsaic, Red Emperor, N4 Pharma, Greggs and Edenville Energy
Faron Pharma raises around €1.34mln from share subscription by existing shareholder
The company said Timo Syrjälä and Acme Investments SPF Sarl, an entity wholly owned by Syrjälä has subscribed for 1,757,375 new ordinary shares at a price of €0.7598 (£0.65) each
Investments and investor services
FTSE 100 closes higher and global stocks rally as trade fears seem to ease
On Wall Street, the Dow Jones Industrial Average is up 287 points at the time of writing
Archive
Proactive news snapshot: Kromek, ITM Power, Rockfire Resources
A glance at some of the day's highlights from the Proactive Investors newswire
Faron Pharma gears up for “pivotal year”; bosses convinced by Traumakine’s potential
Traumakine disappointed in a late-stage ARDS study last year, but further analysis of the data showed that the drug was effective in certain patients, so another trial is in the works